Nirsevimab and Severe RSV Infection: First Report Card

Clinical Takeaway

: Among infants admitted to intensive care during their first RSV season, those recently given nirsevimab were significantly less likely to have RSV infection.

Context

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infection (LRTI) in tens of thousands of infants each year in the United States. Nirsevimab, a single-dose monoclonal antibody approved in 2023, protects against RSV-associated LRTI and hospitalization when administered to infants before their first RSV season. But does it protect against severe disease?

To find out, researchers examined 457 case (RSV-positive) infants and 302 control (RSV-negative) infants from the Overcoming RSV Network surveillance program who were admitted to the intensive care unit (ICU) at 27 hospitals in 24 states during the 2024–2025 RSV season.

Key Results

Administration of nirsevimab ≥1 week before ICU admission was associated with fewer I…

Reviewing Author

Deborah Lehman, M.D.

Disclosures

Nothing to disclose